KR101439783B1 - Maximowiczia Chinensis Extracts For Preventing, Treating Muscular Dystrophy And Manufacturing Method of thereof - Google Patents

Abstract

The present invention relates to a composition containing a Maximowiczia Chinensis extract for preventing and alleviating muscular dystrophy and a method for producing the same. The composition according to an embodiment of the present invention includes a Maximowiczia Chinensis extract obtained by mixing and extracting Maximowiczia Chinensis with C1-4 low class alcohol or an alcohol solution having 50-200 volume% of the same, and may have effects in preventing and alleviating muscular dystrophy. The Maximowiczia Chinensis extract according to the present invention has effects in preventing and alleviating muscular dystrophy by inhibiting the activities of mRNA related to muscle protein destruction and activating the expression of mRNA related to muscle protein synthesis. When the Maximowiczia Chinensis extract uses Maximowiczia Chinensis seeds, muscular dystrophy alleviating effects are very great and do not cause side effects when being used.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention and improvement of muscle atrophy comprising an extract of Omija and a method for preparing the same,

TECHNICAL FIELD The present invention relates to a composition for preventing and improving muscle diseases containing an extract of Omija and a method for producing the same. More specifically, the present invention relates to a method for analyzing mRNA involved in muscle protein degradation, which comprises inhibiting the expression of mRNA and enhancing mRNA expression activity involved in muscle protein synthesis, thereby preventing or ameliorating atrophy symptoms, And to a method for preparing the same.

Muscular dystrophy is caused by various causes such as aging, lack of mechanical stimulation, starvation and cancer. Muscle regression occurs primarily from significant loss of myofibrillar proteins, resulting in decreased muscle and athletic performance. For example, even though motion or other countermeasures (e.g., electrical stimulation) are applied continuously (e.g., 1 to 3% loss of muscle strength per week in astronauts during long-term space flight) As with the conditions, muscle regression inevitably proceeds. Therefore, research on other countermeasures to overcome obstacles to assist astronauts or to improve their ability to perform, either as alternatives to mechanical stimuli or mechanical stimuli, is required. Derived biological material that can help maintain muscle mass under conditions that induce atrophy of myofibrillar proteins with a proper approach to such countermeasures.

Muscle mass has been demonstrated to be a result of the synthesis of muscle proteins and the balance of degradation rates. In the case of muscle protein synthesis, the signaling pathway associated with class I phosphoinositide-3 kinase (PI3K) and Akt / protein kinase B (PKB) on mammalian target rapamycin (mTOR) is known to promote synthetic metabolism. Phosphorylation of mTOR then activates p70 / S6K in its downstream pathway and promotes mRNA translation through phosphorylation of the ribosomal protein component (e. G., S6).

In other words, muscle protein degradation is primarily regulated by the signaling pathway consisting of the forkhead box O (FoxO) and the ubiquitin-proteasome system. In this pathway, decreased activation of Akt promotes the expression of muscle-specific E3 ligase, including atrogin-1 / muscle atrophy F-box (MAFbx) and muscle RING Finger 1 (MuRF1) through FoxO, Respectively.

Importantly, it has been reported that the degree of activity of the muscle lysis pathway may be influenced by several factors in the myotubes and nuclei. First, dexamethasone (DEX), one of the biosynthetic substances of glucocorticoids, promotes muscle atrophy by inhibiting PI3K and Akt activity and increasing FoxO and E3 ligase activity. According to these authors, inhibition of the PI3K / Akt pathway by DEX promotes ubiquitin expression by mutual interference from the FoxO to the MEK / ERK pathway. This interference is believed to be the main mechanism by which gene transcription of E3 ligase (by activation of FoxO) and ubiquitin (by MEK / ERK pathway) occurs simultaneously and degrades unnecessary proteins in the proteasome system.

Second, the heat shock protein (HSP) decreases expression when muscle tissue is atrophy, and conversely, HSP overexpresses it to mitigate muscle atrophy. Recent studies have shown that overexpression of HSP70 inhibits the FoxO3a reporter activity and directly inhibits the ubiquitin E3 ligase promoter activity. HSP is a molecular chefuron that helps protein folding and repairing not only cytoprotection but also protein quality control for various stresses (eg, hypoxia, heat stroke, mechanical stress) . ≪ / RTI > In muscle cells, HSPs are also known to play a role in the organization and maintenance of myofibrils (housekeeping), which is essential for muscle contraction. Therefore, it is reasonable to find a natural product that induces HSP in consideration of the inhibitory effect of HSP70.

Omiza is distributed in the altitude of 200 ~ 1,600m above sea level and is a deciduous deciduous broad-leaved tree that grows widely in Mt. Jiri, Mt. The leaves are 6 ~ 9m long, 7 ~ 10㎝ long, 3 ~ 5㎝ wide, with hairs on the back vein, small teeth on the edge, and wide oval shape. The flower is slightly reddish yellowish white with a diameter of about 1.5㎝. It blooms one by one on the axil of the short branch of newly emerged 3-5. The fruit is strong in sour taste and ripen in red color from August to September, and its length is 0.6 ~ 1.2㎝, and several dogs are hanging down with grape clusters. It is used for ornamental purposes, and the fruit is used for medicinal purposes.

As for the specific prior art, Prior Art 1 (KR 10-2010-0072390 A, published on July 01, 2010) discloses a composition for raw rice wine containing an extract of Omija. However, this is based on the taste and aroma of Omija, and because it is a natural fruit extract, the useful ingredient of Omija can promote health.

Prior Art 2 (KR 10-2006-0119081 A, publication date: November 24, 2006) discloses an extract of Schizandra chinensis having antimicrobial activity, but merely has an antibacterial activity of Schizandra chinensis extract And there is no disclosure of the effect of the atypical shrinkage using the above-mentioned Omiza extract.

BACKGROUND ART [0002] Prior Art 3 (KR KR 10-0854567 B1, publication date: Aug. 26, 2008) relates to an antimicrobial composition containing omija together with amylose and rhodochrosite, and has a high antifungal effect as an additive composition for animal feed , Which is not aware of the effect of muscle atrophy using Omija.

Therefore, conventional prior art is a food composition based on the unique flavor and texture of Omija, or is used as an antibacterial composition prepared on the basis of the antibacterial property of the Omija, and research on the new effect of Omija is insufficient. Therefore, the present invention has been completed on the basis of the characteristics of the muscular atrophy effect of Omija while studying the new effect features of Omija.

KR 10-2010-0072390 A KR 10-2006-0119081 A KR 10-0854567 B1

An object of the present invention is to provide a method for analyzing mRNA involved in muscle protein degradation and improving the activity of mRNA expression involved in muscle protein synthesis while inhibiting the expression of the mRNA to prevent or ameliorate atrophy symptoms, And to provide a composition for preventing and improving atrophy.

Another object of the present invention is to provide a method for preparing a composition for preventing and ameliorating atrophy, which comprises the extract of Omiza.

In order to achieve the above object, the composition for preventing and improving muscle atrophy according to one embodiment of the present invention comprises at least one selected from the group consisting of Maximowiczia chinensis and 1 to 4 carbonated lower alcohols or 50 to 200% And an extract of Schizandra chinensis extract mixed with an aqueous solution, and may have the effect of preventing and improving Muscular Dystrophy.

The composition for preventing or ameliorating atrophy comprising the extract of Omiza may inhibit the expression of any one or more of the group consisting of Atrogin-1 mRNA, MuRF1 mRNA, Myostatin mRNA and SIRT1 mRNA.

The composition for preventing and improving muscle atrophy comprising the extract of Omiza may increase expression of any one or more of the group consisting of PI3K mRNA, Adenosine A1R mRNA, Akt1 mRNA and TRPV4 mRNA.

The atrophy may be caused by one or more of disuse atrophy of muscle, mechanical stimulation member, and denervation of skeletal muscle.

The omiza may be lyophilized after drying at 150 to 210 ° C, and the omija may be in a volume ratio of 1: 3 to 3: 1 with the lower alcohol having 1 to 4 carbon atoms.

The composition for prevention and improvement of muscle atrophy comprising the extract of Omiza may have the effect of reducing muscle fiber bundles, infiltration of inflammatory cells of muscles, and prevention and improvement of local fibrosis.

The composition for preventing or ameliorating atrophy comprising the Schizandra chinensis extract may be a food composition containing 0.1 to 10% by weight of the Schizandra chinensis extract and further comprising a food-acceptable food-aid additive for preventing or improving muscle atrophy .

According to another embodiment of the present invention, there is provided a method for preparing a composition for preventing and ameliorating atrophy comprising an extract of Omija comprising the steps of drying omija at 150 to 210 ° C to prepare dried omija, A lyophilizing step of lyophilizing the lyophilized Schizandra chinensis powder, and a step of lyophilizing the lyophilized schizophyll powder by mixing the lyophilized Schizandra chinensis powder with a lower alcohol having 1 to 4 carbon atoms or a 50 to 200 volume % Alcohol aqueous solution at a volume ratio of 1: 3 to 3: 1 to prepare an extract of Omija at 15 to 35 ° C for 10 to 30 hours. The Omija extract is effective for prevention and improvement of muscular dystrophy It can be an effect.

Hereinafter, the present invention will be described in more detail. The following description is intended to assist in a clear understanding of the present invention only and does not limit the scope of the present invention to the following contents.

The composition for prevention and improvement of muscle atrophy according to one embodiment of the present invention includes at least one composition selected from the group consisting of Maximowiczia chinensis and a lower alcohol having 1 to 4 carbon atoms or an aqueous solution of 50 to 200% And may have the effect of preventing and improving Muscular Dystrophy.

Preferably, the Omiza may be an Omija seed. Omija has unique flavor and excellent antimicrobial power. However, the experimental results showed that the extract of Omija did not improve the muscle atrophy. However, when using Omija seed extract, muscle protein collapse And contributes to the production of muscle protein. Thus, it has been confirmed that it has a very excellent therapeutic effect on muscle atrophy. It can be considered that the omija seed contains a large amount of the active ingredient which is effective for the improvement of muscle atrophy compared to the omija. In addition, since there is no problem such as cytotoxicity due to its low use amount, it is more preferable that the extract of Omija seed is used as a composition for prevention and improvement of muscle atrophy according to the object of the present invention.

A composition for prevention and improvement of muscle atrophy comprising the extract of Omija of the present invention The present invention provides a composition capable of improving the atrophy of Omija itself without mixing with another extract or a drug for the treatment of muscle atrophy, In the case of the atrophic composition, the extract or the medicament may contain the omija extract. However, the omija extract is only used for improving the texture of the composition or multiplying the antimicrobial activity by using the omija, have.

The lower alcohol having 1 to 4 carbon atoms may be ethanol at a concentration of 70 to 100% by weight. When the ethanol is used, an effective ingredient for improving atrophy contained in the omija can be effectively extracted, and when the ethanol concentration is less than 70% by weight, the effect of improving the atrophy of the omija extract may be lowered.

The composition for preventing or ameliorating atrophy comprising the extract of Omiza may inhibit the expression of any one or more of the group consisting of Atrogin-1 mRNA, MuRF1 mRNA, Myostatin mRNA and SIRT1 mRNA.

The composition for preventing and improving muscle atrophy comprising the extract of Omiza may increase expression of any one or more of the group consisting of PI3K mRNA, Adenosine A1R mRNA, Akt1 mRNA and TRPV4 mRNA.

The Omiza extract inhibits the expression of at least one of the above-mentioned Atrogin-1 mRNA, MuRF1 mRNA, Myostatin mRNA and SIRT1 mRNA to inhibit the production of muscle decay proteins, and PI3K mRNA, Adenosine A1R mRNA, Akt1 mRNA, and TRPV4 mRNA, thereby increasing the production of muscle-producing proteins, thereby showing an improvement effect on atrophy.

The atrophy may be caused by one or more of disuse atrophy of muscle, mechanical stimulation member, and denervation of skeletal muscle.

The above-mentioned disuse atrophy of muscle means that the muscle thickness is reduced by restricting the activity due to aging, disease, long bed life, casting, and the like. The above-mentioned Omiza extract has excellent improvement effect on insoluble muscle atrophy.

The atrophy is accompanied by various clinical diseases such as peripheral nerve injury, cancer and hematemesis, as well as long-term bed rest, limb gypsum fixation and aging process. In general, muscle atrophy is accompanied by physiological, histochemical and biochemical changes resulting from a decrease in muscle protein, leading to impairment of the inherent function of the skeletal muscle.

The denervation of the skeletal muscle is accompanied by a decrease in muscle mass and muscle strength, a decrease in the thickness of the muscle fiber, a change in the muscle fiber type in which the root fiber is transformed into the inner muscle fiber, ≪ / RTI >

This mechanism of muscle atrophy is due to the increase in apoptosis of muscle cells due to oxidative damage, because the number of mitochondria in the denervated dominant muscle cells is decreased and the function is differentiated and the production of ROS is increased in the mitochondria. .

The above-mentioned Schizosaccharum can be lyophilized after drying at 150 to 210 ° C.

When the omija is dried, there is an advantage in commercialization. Preferably, when the omija seed is dried, the active ingredient having the effect of improving the atrophy is more activated. That is, in the case of using the same concentration of Omija seeds when the Omija seeds are dried and extracted, the dryness of the Omija seeds is more improved than the case where the extract is prepared by freeze-drying the Omija seed immediately without drying, A more favorable effect is obtained.

Particularly, when the drying temperature is lower than 150 ° C, the above effect is hardly obtained. When the temperature is higher than 210 ° C, the effect of preventing the atrophy of Omija seed extract is rather reduced. Respectively.

More preferably, the Schizosacchis seeds may be lyophilized after drying at 170 to 190 ° C. In the case of drying omija seeds in the temperature range above, it is presumed that the extract of omija seed has the most effect to prevent atrophy, and the most effective ingredient to prevent atrophy is presumed to be contained.

The oligomer may have a volume ratio of 1: 3 to 3: 1 with the lower alcohol having 1 to 4 carbon atoms. By the above range, it is useful for extracting an effective substance which is effective for improving atrophy.

Preferably, the seeds of Omija seeds are used, and the seeds of Omija seeds may be 1: 2 to 1: 3 by volume of the lower alcohol having 1 to 4 carbon atoms. In the case of using Omija seed, not only the effect of improving muscle atrophy is excellent, but also the effective substance which is effective in improving muscle atrophy can be extracted by the above range. When the alcohol content is lower than the above range, the extraction amount of the effective substance effective for improving the atrophy contained in the Omija seed is decreased rapidly. When the alcohol content is higher than the above range, the alcohol is volatilized, There is a problem in that an effective substance effective for improvement of muscle atrophy contained in the extract of the present invention is lost.

The composition for preventing or ameliorating atrophy comprising the Schizandra chinensis extract may be a food composition containing 0.1 to 10% by weight of the Schizandra chinensis extract and further comprising a food-acceptable food-aid additive for preventing or improving muscle atrophy .

And preferably 0.1 to 0.17% by weight of the above-mentioned Omija extract. By the above range, it is possible to exhibit an improvement effect on atrophy in various patient groups as a range without cytotoxicity. In particular, when the ratio is in the above range, the absorption rate of the Omija extract is the highest, and thus the improvement effect on the atrophy can be most excellent.

The composition for prevention and improvement of muscle atrophy comprising the extract of Omiza may have the effect of reducing muscle fiber bundles, infiltration of inflammatory cells of muscles, and prevention and improvement of local fibrosis.

According to another embodiment of the present invention, there is provided a method for preparing a composition for preventing and ameliorating atrophy comprising an extract of Omija comprising the steps of drying omija at 150 to 210 ° C to prepare dried omija, A lyophilizing step of lyophilizing the lyophilized Schizandra chinensis powder, and a step of lyophilizing the lyophilized schizophyll powder by mixing the lyophilized Schizandra chinensis powder with a lower alcohol having 1 to 4 carbon atoms or a 50 to 200 volume % Alcohol aqueous solution at a volume ratio of 1: 3 to 3: 1 to prepare an extract of Omija at 15 to 35 ° C for 10 to 30 hours. The Omija extract is effective for prevention and improvement of muscular dystrophy It can be an effect.

In the pulverizing step, the average particle diameter of the ground powder of omija or omija may be 0.03 mm to 1 mm. When the average particle diameter is less than 0.03 mm, the pulverized material clumps and the extraction efficiency of the active ingredient decreases. When the average particle diameter exceeds 1 mm, there is a problem that the extraction efficiency of the effective ingredient for improving the atrophy of the endosymbion of the omisza is low.

When the temperature is lower than 15 ° C., the yield of the effective substance for improving the atrophy among the active ingredients contained in the omija may be lowered. When the temperature is higher than 35 ° C., the alcohol is partially volatilized and the omija seed There is a problem that an effective substance effective for improvement of muscle atrophy contained in the extract is lost.

Therefore, it is preferable to slowly extract for 10 to 30 hours in the above temperature range to obtain an Omija extract.

More preferably at 19 to 28 DEG C for 20 to 28 hours. In the above range, the yield of the effective substance is the highest, and the effect on the atrophy can be most excellent.

The composition for preventing and improving muscle atrophy comprising the extract of Omija may be separated into a hydrodistillation process at 170 to 300 ° C for 1 to 5 hours after the step of preparing the Omija extract.

The Omiza extract having the effect of preventing and improving muscle atrophy according to the present invention has an effect on preventing and improving muscle atrophy by inhibiting the activity of mRNA involved in muscle protein collapse and increasing the activity of mRNA expression involved in muscle protein synthesis.

In particular, the extract of Omiza, which prevents or ameliorates the symptoms of the atrophy, has the advantage that the effect of improving the atrophy is very excellent when using the Omiza seed, and there is no side effect due to use.

Therefore, in the case of using the extract of Omija to prevent or ameliorate the symptoms of the atrophy according to the present invention, the use of the functional food as an application for improvement of the muscle atrophy effect, apart from the antibacterial effect of the conventional Omija or the improvement of the texture based on the flavor of the Omija itself, And can be widely used for manufacturing various formulations such as pharmaceutical preparations and the like.

FIG. 1 relates to the thickness change of the exposed (skin-removed) calf muscle after administration of Omija seed extract in NTX (femoral nerve triceps) -induced atrophy model.
FIG. 2 is a graph showing the weight change of the calf muscles after administration of Omija seed extract in the NTX (femoral nerve triceps) -induced atrophy model.
Figure 3 relates to body weight changes in an atrophy model induced by HS (hypoglossal method).
Figure 4 relates to the change in the muscle thickness of the calf in an asymmetric model induced by HS (lower limb method).
Figure 5 relates to the change in gastrocnemius thickness after muscle exposure in an asymmetric model induced by HS (lower limb method).
Figure 6 relates to the change in gastrocnemius thickness in an atrophy model induced by HS (hypotensive method).
Figure 7 relates to the histological changes of the gastrocnemius in an asymmetric model induced by HS (hypoglossal method).

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

[Production Example: Preparation of Omiza Extract]

The seeds of Omija were collected from Mungyeong, Kyungbuk Province and then completely dried at 180 ° C using furnace (Korea Science and Technology, Korea) and then pulverized to 0.15 to 0.2 mm on an average particle size basis. (Buchi Rotavapor R-144, Switzerland) and then hydrolyzed for 3 hours at 190 ° C. The resulting solution was filtered through a rotary vacuum evaporator (Buchi Rotavapor R-144, Switzerland) Respectively.

[Experimental Example 1: Test for improving atrophy by nerve shear]

1. Test Method

- Experimental animals

 Sixty healthy SPF 6-week-old male ICR mice were obtained for 7 days and then weighed after 2 weeks of NTX (femoral nerve triceps) weight (41.11 ± 3.71 g, 33.00 ~ 47.10 g; NTX muscle atrophy group: 41.51 ± 3.54 g and 34.30 to 49.50 g) and calf thickness (4.50 ± 0.41 mm, 4.03 to 5.28 mm, and 3.26 ± 0.18 mm and 3.00 to 3.60 mm in NTX muscle atrophy group, respectively) Were selected. All experimental animals were fasted for 18 hours at NTX operation day, drug administration start date, and final autopsy day (negative water was also freely supplied during this period), and individuals were identified with picric acid.

- Group separation (total 6 groups; 10 per group)

(1) Sham vehicle control: Control group

(2) NTX control: sciatic nerve sheath and sterilized distilled water control

(3) Oxymetholone: sciatic nerve cleavage and oxymetholone 50 mg / kg Control drug

(4) Schizandra chinensis Extract (SSE) 300: sciatic nerve cleavage and Schizandra chinensis extract 300 mg / kg

(5) Schizandra chinensis Extract (SSE) 150: Sciatic nerve cut and Schizandra chinensis extract 150mg / kg Controlled drug group

(6) Schizandra chinensis Extract (SSE) 75: Schizophrenia and Schizandra chinensis extract 75 mg / kg Control group.

- induction of muscle atrophy

Previous methods [Ogawa et al., 2005; According to Nagpal et al., 2012, the muscles of the right femur were transversally incised in the following sequence to expose the sciatic nerve, and then the sciatic nerve of about 5 mm was cut and excised (see FIG. 2 below). In the gastric control group, the sciatic nerve was exposed and the abdomens were closed without resection.

-drug injection

 The omija seed extract was suspended in sterilized distilled water, and the animals were orally administered with a 1 ml syringe attached with a metal zonde for 28 days from 2 weeks after the administration of NTX at a dose of 10 ml per kg of body weight. Oxymetholone was also added to the omija seed extract . In the stomach surgery and NTX control group, only the same volume of sterilized distilled water was orally administered instead of Omija seed extract or oxymetholone. The dose of oxymetholone used in this study was 50 mg / kg based on previous animal studies [Pavlatos et al., 2001; Isaacs et al., 2011] were selected as dosing doses and Omija seed extracts were selected as 300, 150 and 75 mg / kg.

- Observations

Weight, calf thickness, and calf muscle weight were examined to evaluate the effect of Omija seed extract on muscle atrophy.

- Weight measurement

Body weights were measured with an electronic balance (Precisa Instrument, Moosmattstr, Switzland).

- Calf muscle thickness and weight measurement

Measurements of the calvarial muscle were measured with an electronic caliper (Mytutoyo, Tokyo, Japan) on the day of NTX administration, on the day before the drug administration, on the day of administration, on days 1, 7, 14, 21 and 27 and on the day of sacrifice. The thickness of the muscle of the calf was measured after the muscle was exposed at the sacrifice day. On the other hand, the thickness measurement change of the calf muscle was calculated by the following equation.

(Mm) = calf muscle thickness at sacrifice - calf muscle thickness at the first administration day

The weight of the calf muscle was carefully measured and measured as an electronic balance after the calf muscle was carefully separated from the tibia on the day of sacrifice. The relative weight was also divided by body weight in order to measure the relative weight.

2. Test results

- Changes in body weight and weight gain

As a result of this experiment, significant changes in body weight and weight gain related to NTX or the administered substance were not observed for 6 weeks before the experiment. In the NTX control group, the weight gain during 4 weeks of administration was -8.99% as compared with the control group. In the oxymetholone, Omija seed extract 300, 150 and 75 mg / kg administration groups, 24.42, -5.81, 13.95 and -2.33%, respectively.

The weight change after administration of Omija seed extract in the NTX-induced atrophy model is shown in Table 1 below.

Groups Body weights (g) Body weight gains during test article treated periods (g) [B-A] At NTX At 21 days after NTX, first administration [A] Sacrifice
[B] Controls Sham 30.58 0.95 36.05 ± 2.91 39.83 + - 3.67 3.78 ± 1.18 NTX 30.84 1.58 36.38 ± 3.06 39.82 + 2.91 3.44 ± 1.23 Oxymetholone 31.00 ± 1.70 36.71 + - 3.30 40.99 + - 4.62 4.28 ± 1.79 SSE treated 300 mg / kg 30.26 + - 2.31 35.74 ± 3.96 38.98 + - 5.52 3.24 ± 2.19 150 mg / kg 30.55 + 1.01 35.70 ± 1.62 39.62 ± 1.72 3.92 ± 0.88 75 mg / kg 31.06 ± 1.49 35.91 + - 3.02 39.27 + - 4.06 3.36 1.51

(Mean ± SD, SSE = Omija seed extract, NTX = femoral nerve triceps)

- Change in calf thickness

As a result of using NTX 2 weeks after the reduction of calf thickness, only a decrease in calf thickness was observed in the NTX control group (p <0.01) compared to the gastric control group 1 day before the start of drug administration, , And consequently, the change in calf thickness during the 4-week administration period was also significantly (p <0.01) lower than the gastric surgery control group. On the other hand, in the oxymetholone and Omiza seed extract 300 and 150 mg / kg administration groups, the calf thickness was significantly increased (p <0.01 or p <0.05) compared to the NTX control group 7 days after the start of administration, (P <0.01) than those of the NTX control group. In addition, the increase in calf thickness was significantly increased in the 75 mg / kg group of Omija seed extract (p <0.01) compared to the NTX control group, and the change in calf thickness during the administration period was also significantly higher than that of the NTX control group (p < 0.01), respectively.

In the NTX control group, the change in calf thickness during the 4 weeks of drug administration was -304.05% as compared with the control group. In the oxymetholone, Omija seed extract 300, 150 and 75 mg / kg administration groups, 76.20 and 85.52 , 79.77 and 69.45%, respectively.

- Changes in calf thickness after muscle exposure

In the NTX control group, there was a significant decrease in calf thickness after the muscle exposure (p <0.01) compared to the control group. However, oxymetholone and all Omija seed extract groups showed significant (p <0.01) An increase in calf thickness was recognized.

In the NTX control group, the calf thickness after the muscle exposure was -43.71% compared to the control group, and the oxymetholone, Omija seed extract 300, 150 and 75 mg / kg groups had 21.31, 22.95, 15.25 and 14.79 %, Respectively.

- Changes in calf muscle weight

In NTX control group, the absolute and relative weight of calf muscle was significantly decreased (p <0.01) compared to the control group, but oxymetholone and all Omija seed extract groups were significantly higher than NTX control group (p <0.01) An increase in muscle weight was recognized.

In the NTX control group, the absolute calf muscle weight was -57.83% compared to the control group, and 75.69, 78.00, 63.69 and 44.55% of the oxymetholone, Omija seed extract 300, 150 and 75 mg / Respectively.

In the NTX control group, the relative weight of calf muscle relative to body weight was -58.42% higher than that of the control group, and that of oxymetholone, Omija seed extract 300, 150 and 75 mg / kg were 72.56, 81.93, 65.26 And 47.22%, respectively.

Table 2 below shows the change in muscle thickness of the calf after administration of the Omija seed extract in an NTX-induced model of muscle atrophy.

Groups Calf thicknesses (mm) Changes after test article treated periods (mm)
[BA] At NTX At 21 days after NTX, first administration [A] Sacrifice
[B] Controls Sham 3.31 ± 0.15 4.46 ± 0.28 4.71 ± 0.22 0.25 0.28 NTX 3.34 ± 0.17 3.21 + - 0.14 ^a 2.71 ± 0.07 ^a - 0.50 0.11 ^a Oxymetholone 3.30 ± 0.13 3.24 ± 0.16 ^a 3.12 ± 0.13 ^ab - 0.13 + 0.22 ^ab SSE treated 300 mg / kg 3.27 ± 0.14 3.23 ± 0.14 ^a 3.15 ± 0.17 ^ab - 0.08 + 0.24 ^ab 150 mg / kg 3.30 ± 0.13 3.25 ± 0.17 ^a 3.14 ± 0.17 ^ab - 0.11 + 0.17 ^ab 75 mg / kg 3.27 ± 0.12 3.27 ± 0.17 ^a 3.11 ± 0.18 ^ab - 0.16 ± 0.17 ^ab

(Mean ± SD, SSE = Omija seed extract, NTX = femoral nerve triceps, ^a p <0.01 compared with sham control by ANOVA test, ^b p <0.01 compared with NTX control by ANOVA test)

Referring to FIG. 1, a significant reduction in the amount of exposed exposed calf muscle thickness was observed in the NTX-induced group compared with the normal control group. However, it can be seen that remarkably occur an increase in thickness compared with the NTX control group, group of oxymetholone and Schisandra chinensis seed ^{extract. (A p <0.01 as compared} with sham control by ANOVAtest, b p <0.01 as compared with NTX control by ANOVA test)

Referring to FIG. 2, in the NTX control group, a significant absolute / relative weight loss of the calf muscle occurred compared to the normal control group. However, in the oxymetholone treated group and the Omija seed extract treated group, the weight gain of the calf muscle was significantly greater than that of the NTX control group. ^{(A p <0.01 as compared with} sham control by ANOVAtest, b p <0.01 as compared with NTX control by ANOVA test)

[Experimental Example 2: Test for improving the atrophy by the lower limb method]

1. Test Method

- Experimental animals

Sixty-seven 7-month-old SPF ICR female mice were obtained and weighed for 37 days before weighing (53.131 ± 5.24g, 48.00 ~ 61.40g, HS muscular atrophy group: 52.77 ± 5.83g, 43.50-64.70g) And the calf thickness (normal medium control group: 3.42 ± 0.17 mm, 3.13 to 3.64 mm; HS (hind-limb suspension), muscle atrophy group: 3.42 ± 0.14 mm, 3.16 to 3.68 mm) All animals were fasted for 18 hours at the start of the drug administration and at the final autopsy, and individuals were identified with picric acid

- Experimental group (total 6 groups; 6 per group)

(1) Intact vehicle control: Normal medium control

(2) HS control: HS and sterilized distilled water control

(3) Oxymetholone: HS and oxymetholone 50 mg / kg Control group

(4) SSE 150: HS and Ominja seed extract 150 mg / kg group

(5) SSE 100: HS and Omiza seed extract 100 mg / kg group

(6) SSE 50: HS and Omija seed extract 50 mg / kg group

- Experimental model

Previous methods [Desaphy et al., 2010; According to Onda et al., 2011, an elastic tape is attached to the tip of the tail to attach a thin thread, and the opposite end is fixed to the upper wire netting of the mouse cage using a clip, Lt; RTI ID = 0.0 &gt; 40 &lt; / RTI &gt; HS was administered for 28 days from the start of administration to induce insulin - like atrophy of the fusiform muscles. In the normal medium control group, HS was not performed and the Fuji movement was made free.

- drug injection

The omija seed extract was suspended in sterilized distilled water, and the animals were orally administered at a dose of 10 ml per kg of body weight using a 1 ml syringe with a metal zonde for 28 days once a day starting from the HS start day. Oxymetholone was also added to the omija seed extract In the same way, oral sterilized distilled water was used for oral administration. In normal medium and HS control, only sterilized distilled water of the same volume was orally administered instead of Omija seed extract or oxymetholone. The dose of oxymetholone used in this study was 50 mg / kg based on previous animal studies [Pavlatos et al., 2001; Isaacs et al., 2011] were selected as dosing doses, and 150, 100, and 50 mg / kg of Omija seed extract were selected.

- Observations

The effects of Omija seed extract on muscle atrophy were evaluated by observing body weight, calf thickness, gastrocnemius weight, thickness, and histological changes. The expression pattern of mRNA, which is known to be involved in muscle protein degradation and synthesis, was also evaluated in gastrocnemius muscle.

The expression of mRNAs involved in the disruption and synthesis of muscle proteins: Atrogin-1, muscle RING-finger protein-1 (MuRF1), PI3k p85α, adenosine A1 receptor (A1R), transient receptor potential cannon subfamily V member 4 (TRPV4) myostatin and Sirtulin 1 (SIRT1)

- General histopathological observation

The mean muscle fiber diameter, the number of infiltrating inflammatory cells in the muscle bundle, and the proportion of collagen fibers accounted for.

- statistics

Values were expressed as mean ± SD, and significance was verified as ANOVA test.

2. Test results

- Changes in body weight and weight gain

As a result, in the HS control group, a significant decrease (p <0.01 or p <0.05) in body weight was observed from the 7th day after HS start to the normal medium control group. (P <0.01) compared to the control group. On the other hand, the increase in body weight (p <0.01 or p <0.05) of oxymetholone and omija seed extract 150 and 100 mg / kg, respectively, (P <0.01) than those of the HS control group. In the 50 mg / kg group of Omiza extract, the body weight gain was more significant (p <0.05) than that of the HS control group after 27 days from the start of the administration, and the body weight gain during the 28 days of administration was also significantly higher than that of the HS control group ) Increase

In the HS control group, the amount of weight gain during 4 weeks of administration was -2364.58% as compared to that of the normal medium control group. In the oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, 45.16, 61.26, 47.64, 36.60%, respectively.

- Change in calf thickness

From 7 days after the start of HS, decrease in calf thickness started to be significant (p <0.01) in the HS control group as compared to the normal medium control group, and was recognized during the whole experiment period. As a result, (P <0.01) compared to the normal control group. On the other hand, in oxymetholone, 150, 100 and 50 mg / kg group, the increase in calf thickness was significantly increased (p <0.01 or p <0.05) The calf thickness variation was also significantly (p <0.01) higher than the HS control group.

In the HS control group, the change in calf thickness during the 4 weeks of drug administration was -1357.38% compared to the normal control group. In oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, the change in calf thickness was 30.86, 53.02, 28.64 and 16.78%, respectively.

- Changes in gastrocnemius thickness after muscle exposure

In the HS control group, the decrease in gastrocnemius thickness was significantly (p <0.01) lower than that in the normal control group. However, oxymetholone and all of the Omija seed extract group were significantly (p <0.01) An increase in thickness was recognized.

In the HS control group, the calf thickness was -37.38% as compared with the normal control group, and the oxymetholone, Omija seed extract 150, 100 and 50 mg / kg groups had 22.68, 30.69, 23.92 and 10.30% Respectively.

- Variation of gastrocnemius weight

(P <0.01) decreased in the HS control group compared to the normal control group, but the oxymetholone and all the Schizandrae extract group showed a significant increase in gastrocnemius weight (p <0.01) compared to the HS control group . On the other hand, the relative weight of gastrocnemius showed no significant change in all experimental groups including HS control group.

In the HS control group, the absolute weight of the gastrocnemius showed a change of -40.76% as compared with the normal medium control group, and that of oxymetholone, Omija seed extract 150, 100 and 50 mg / kg was 21.90, 33.14, 22.29 and 13.11% Respectively.

In the HS control group, the relative weight of the gastrocnemius relative to body weight was -1.00% compared to the normal medium control group. In oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, -7.80 and -3.51, 4.88 and -7.33%, respectively.

- Changes in gastrocnemius Atrogin-1 mRNA expression

(P <0.01) gonadotropin Atrogin-1 mRNA expression was increased in the HS control group compared to the normal medium control group, whereas the oxymetholone and omija seed extract groups at 150, 100 and 50 mg / <0.01). Atrogin-1 mRNA expression was decreased.

In the HS control group, Atrogin-1 mRNA expression of gastrocnemius was 290.67% higher than that of the normal control group. In oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, -40.96, -53.11, -42.66 And -34.98%, respectively.

- Changes in gastrocnemius MuRF1 mRNA expression

Significant (p <0.01) increased gastrocnemius MuRF1 mRNA expression was observed in the HS control group compared to the normal medium control group. However, in the oxymetholone and Omiza seed extract 150, 100 and 50 mg / kg administration groups, ) MuRF1 mRNA expression was reduced.

In the HS control group, the expression of gastrocnemius MuRF1 mRNA was 220.67% as compared with that of the normal medium control group, and -30.93, -53.69, -28.90 and -30.93, respectively, in the oxymetholone and Omiza seed extract 150, 100 and 50 mg / 22.56%, respectively.

- Changes in gastrocnemius PI3K mRNA expression

PI3K mRNA expression was significantly increased (p <0.01) in the HS control group compared to the normal medium control group, but PI3K mRNA expression was significantly increased in the 150, 100 and 50 mg / mRNA expression was increased. On the other hand, no significant changes in expression of PI3K mRNA were observed in oxymetholone treated group compared to HS control group.

In the HS control group, PI3K mRNA expression of the gonadotropin was 195.67% higher than that of the normal control group. In the oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, 4.11, 34.67, 21.87 and 9.24% Respectively.

- Changes in gastrocnemius Akt1 mRNA expression

Significant (p <0.01) gonadotropin Akt1 mRNA expression was observed in the HS control group compared with the normal medium control group. However, in the 150, 100 and 50 mg / kg group treated with Omija seed extract, &Lt; 0.05), indicating an increase in Akt1 mRNA expression. On the other hand, no significant change in Akt1 mRNA expression was observed in oxymetholone treated group compared to HS control group.

In the HS control group, the expression of Akt1 mRNA was 90.50% higher than that of the normal control group. In the oxymetholone, Omija seed extract 150, 100 and 50 mg / kg administration groups, the changes of 4.20, 65.97, 48.12 and 32.63% Respectively.

- Changes in adenosine A1R mRNA expression in gastrocnemius

Adenosine A1R mRNA expression was significantly increased in the HS control group compared to the normal control group. However, Adenosine A1R mRNA expression was significantly increased in the 150, 100 and 50 mg / kg groups of Omija seed extracts compared to the HS control group (p <0.01) An increase was recognized. In the oxymetholone-treated group, however, the adenosine A1R mRNA expression was slightly increased compared with the HS-treated group.

In the HS control group, adenosine A1R mRNA expression was 42.67% higher than that of the normal control group. In the oxymetholone, Omiza seed extract 150, 100 and 50 mg / kg administration groups, 27.45, 375.70, 231.07 and 188.32% Change.

- Changes in gastrocnemius TRPV4 mRNA expression

The TRPV4 mRNA expression was significantly increased in the HS control group compared to the normal control group, but the TRPV4 mRNA expression was significantly increased (p <0.01) in the 150, 100 and 50 mg / kg group treated with Omija seed extract It was acknowledged. On the other hand, oxymetholone treated group did not show any significant difference compared to HS control group, but mild TRPV4 mRNA expression was increased.

In the HS control group, the expression of gonadotropin TRPV4 mRNA was 37.50% higher than that of the normal control group, and the change of 36.12, 160.48, 117.45 and 85.21% in the oxymetholone, Omija seed extract 150, 100 and 50 mg / Respectively.

- Changes in myostatin mRNA expression in gastrocnemius muscle

Significant (p <0.01) gonadal myostatin mRNA expression was increased in the HS control group compared to the normal medium control group but significantly higher in the oxymetholone and omija seed extract groups of 150, 100 and 50 mg / kg than in the HS control group (p <0.01 Or p < 0.05).

In the HS control group, myostatin mRNA expression was 607.00% higher than that of the normal control group, and -41.37, -56.01, -42.48, and -41.47, respectively, in the oxymetholone, Omija seed extract 150, 100 and 50 mg / 39.46%, respectively.

- Changes in gastrocnemius SIRT1 mRNA expression

In the HS control group, the expression of gastrocnemic SIRT1 mRNA was significantly increased (p <0.01) compared to the normal control group, but the oxymetholone and Omiza seed extracts were significantly (p <0.01) Or p < 0.05), indicating a decrease in SIRT1 mRNA expression.

In the HS control group, the gastrocnemius SIRT1 mRNA expression was 503.83% higher than that of the normal medium control group, and -39.53, -60.25, -40.82, and -40.82, respectively, in the oxymetholone and Omiza seed extract 150, 100 and 50 mg / 28.43%, respectively.

The following Table 3 relates to the muscle protein-related mRNA changes in the gastrocnemius in the HS-induced myosinocyte model.

Groups
Targets Controls SSE treated mice (mg / kg) Intact HS Oxymetholone 150 100 50 Atrogin-1 1.00 ± 0.00 3.91 ± 0.52 ^a 2.31 ± 0.37 ^ab 1.83 ± 0.16 ^ab 2.24 ± 0.38 ^ab 2.54 ± 0.44 ^ab MuRF 1 1.00 ± 0.00 3.21 ± 0.30 ^a 2.22 ± 0.26 ^ab 1.49 ± 0.18 ^ab 2.28 ± 0.47 ^ab 2.48 ± 0.25 ^ab PI3K p85α 1.00 ± 0.00 2.96 + 0.13 ^a 3.08 ± 0.55 ^a 3.98 ± 0.20 ^ab 3.60 ± 0.38 ^ab 3.23 ± 0.15 ^ac Akt 1 1.00 ± 0.00 1.91 + 0.48 ^a 1.99 ± 0.69 ^a 3.16 ± 0.54 ^ab 2.82 ± 0.17 ^ab 2.53 + - 0.22 ^ac Adenosine A1R 1.00 ± 0.00 1.43 + - 0.61 1.82 ± 0.69 ^a 6.79 ± 0.97 ^ab 4.72 + 0.99 ^ab 4.11 ± 1.23 ^ab TRPV4 1.00 ± 0.00 1.38 + - 0.55 1.87 + - 0.61 ^a 3.58 ± 0.68 ^ab 2.99 ± 0.79 ^ab 2.55 ± 0.48 ^ab Myostatin 1.00 ± 0.00 7.07 ± 1.71 ^a 4.15 ± 1.19 ^ab 3.11 ± 0.66 ^ab 4.07 ± 0.84 ^ab 4.92 + 0.71 ^ac SIRT1 1.00 ± 0.00 6.04 ± 1.17 ^a 3.65 ± 0.87 ^ac 2.40 0.72 ^ab 3.57 ± 0.59 ^ab 4.32 + 0.66 ^ac

(Mean ± standard deviation, relative expressions / 18s ribosomal RNA, SSE = Schizandra chinensis extract, HS = unstable method; MuRF1 = muscle RING-finger protein-1; PI3k = phosphatidylinositol 3-kinase; A1R = A1 receptor; TRPV4 = transient receptor potential cation cannel subfamily V member 4; SIRT1 = Sirtulin 1; ^a p <0.01 compared with intact control by ANOVA test; ^b p <0.01 and ^c p <0.05 compared with HS control by ANOVA test)

The following Table 4 relates to the histomorphological changes of the gastrocnemius in the HS-induced atrophy model.

Groups Histomorphometry of the gastrocnemius muscle bundles Mean muscle fiber diameters (μm / fiber) Infiltrated inflammatory cell numbers (cells / mm ² ) Collagen fiber occupied regions (% / mm ² ) Controls Intact   55.43 + - 10.63    8.00 ± 2.10    3.58 ± 2.14 HS 20.91 + 1.82 ^a 224.83 ± 98.05 ^a 31.59 ± 2.45 ^a Oxymetholone 31.43 ± 3.76 ^ab 72.67 ± 34.11 ^ab 21.07 ± 3.79 ^ab SSE treated 150 mg / kg 39.61 ± 2.36 ^ab 34.00 ± 7.75 ^ab 8.82 ± 2.26 ^ab 100 mg / kg 31.47 ± 5.13 ^ab 78.33 ± 24.29 ^ab 19.63 ± 2.69 ^ab 50 mg / kg 28.84 ± 8.87 ^ab 107.33 ± 27.07 ^ab 24.68 ± 4.59 ^ab

(Values are mean ± SD; SSE = Schisandra seed extract; HS = not elevation ^{method, a p <0.01 as compared with} intact control by ANOVA test; b p <0.01 as compared with HS control by ANOVA test)

Table 5 below shows the changes in gastrocnemius myostatin in the HS-induced atrophy model.

Groups Myostatin (fibers / mm ² ) Controls Intact 7.17 + 1.83 HS 78.83 ± 2.19 ^a Oxymetholone 30.674 ± .59 ^ab SSE treated 150 mg / kg 21.33 6.12 ^ab 100 mg / kg 33.00 ± 5.66 ^ab 50 mg / kg 54.50 ± 7.92 ^ab

(Mean ± SD, relative expressions / 18s ribosomal RNA

SSE = Omija seed extract; HS = not elevated, ^a p <0.01 compared with intact control by ANOVA test; ^b p <0.01 compared with HS control by ANOVA test)

Referring to FIG. 3, weight loss occurred on the 7th day in the HS-induced group as compared with the normal control group (arrow day 7). However, significant increases in body weight gain were observed in the oxymetholone-treated group and in the SSE and 100 mg / kg-treated group compared to the HS-treated group at 21 days after the administration and in the SSE 50 mg / kg treated group, Day 0: Day 1: Day 1: Day 1: Day 1: Day 28: Day 28: Day of sacrifice or day of sacrifice † fasting days (overnight ^{fasting); a p <0.01 as compared} with intact control by ANOVAtest; b p <0.01 and c p <0.05 as compared with HS control by ANOVA test)

Referring to FIG. 4, in the HS control group, a significant decrease in the calf muscle was noted at day 7 than the normal control group (arrow). However, in the oxymetholone group and the omija group, the increase in the thickness of the calf muscle was significantly prominent on day 7 compared to the HS control group (mean ± SD, SSE = Omija seed extract, HS = Day 0 or day of the first day of the study; Day 0: Day of first administration; Day 28: Day 28 or day of sacrifice; † Fasting days (overnight abstinence); ^a p <0.01 as compared with intact control by ANOVA test; ^b p <0.01 as compared with HS control by ANOVA test)

Referring to FIG. 5, the HS control group showed a significant decrease in the absolute gastrocnemius weight compared to the normal control group. However, the administration of oxymetholone and Omija seed extract showed a marked increase in absolute gastrocnemius weight compared to HS control. (Mean ± SD, SSE: Schizandra chinensis extract, HS = not elevated, ^a p <0.01 compared with intact control by ANOVA test, ^b p <0.01 compared with HS control by ANOVA test

Referring to FIG. 6, the HS control group showed a significant decrease in the absolute gastrocnemius weight compared to the normal control group. However, oxymetholone group and Schisandra chinensis seed extract administration group showed an increase in significant absolute gastrocnemius muscle weight compared to HS control group (figure mean ± SD, SSE:. Chinensis Seed Extract, HS = not elevation ^{method, a p <0.01 as compared with} intact control by ANOVA test, ^b p <0.01 compared with HS control by ANOVA test)

7, in the HS control group, a decrease in the number of muscle fibers (average fiber diameter reduction), inflammatory cell infiltration (increase in the average number of inflammatory cells), local fibrosis (increase in collagen fibers occupied area, sirus red stain Red color) was increased compared to the normal control group. However, these atrophic lesions significantly decreased dose - dependently on the administration of Omija seed extract (A - C = normal control group; D - F = HS control group; G - I = oxymetholone group; J - L = SSE 150 mg / kg SSE = Schizandra chinensis extract, HS = not shown, Scale bars = 40 μm), M - O = SSE 100 mg / kg, P - R = SSE 50 mg /

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.

Claims (8)

An extract of Schizandra chinensis and an extract of Schizandra chinensis mixed with 1 to 4 carbon lower alcohols or a 50 to 200% by volume alcohol aqueous solution thereof,
Muscular Dystrophy Prevention and improvement effects that have
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method of claim 1, wherein
Wherein said composition inhibits expression of any one or more of the group consisting of Atrogin-1 mRNA, MuRF1 mRNA, Myostatin mRNA and SIRT1 mRNA
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method of claim 1, wherein
Wherein said composition increases expression of any one or more of the group consisting of PI3K mRNA, Adenosine A1R mRNA, Akt1 mRNA and TRPV4 mRNA
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method of claim 1, wherein
The atrophy is caused by at least one of disuse atrophy of muscle, mechanical stimulation member, and denervation of skeletal muscle
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method according to claim 1,
The Schizosaccharomyces pomaceae is lyophilized after drying at 150 to 210 ° C,
Wherein the organophosphorus is in a volume ratio of 1: 3 to 3: 1 with the lower alcohol having 1 to 4 carbon atoms
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method according to claim 1,
Wherein said composition has a preventive and ameliorative effect on reduction of muscle fiber bundles, inflammatory cell infiltration of muscles, and local fibrosis
A composition for preventing and improving muscle atrophy comprising an extract of Omija. The method according to claim 1,
Wherein said Omiza extract is contained in an amount of 0.1 to 10% by weight,
A food composition for preventing or ameliorating atrophy, which further comprises a food-acceptable food-aid additive. An omija drying step of drying omiza at 150 to 210 DEG C to produce dried omija,
Crushing the dried omiza to produce an omija powder,
A lyophilizing step of lyophilizing the above-mentioned schizophyll powder to prepare a lyophilized Schizosaccharum powder;
The lyophilized Schizandra chinensis powder is mixed with a lower alcohol having 1 to 4 carbon atoms or a 50 to 200 volume% alcohol aqueous solution thereof in a volume ratio of 1: 3 to 3: 1, and the Schizosaccharomyces japonica extract at 15 to 35 ° C for 10 to 30 hours Comprising the steps of:
The above-mentioned Schizandra chinensis extract has the effect of preventing and improving Muscular Dystrophy
A method for preparing a composition for preventing and improving muscle atrophy comprising an extract of Omija.

Images